A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)
- EudraCT / EU CT No
- 2022-501560-17-00
- Protocol No
- MK1026-010
Trial information
- Medical condition
- R/R CLL/SLL
- Trial phase
- Phase 3
- Sponsor
- MSD
- Start date
- 02/07/2026
- Main objective
- PFS